“the next version, which is going in animal studies now, will be in humans hopefully next year, should expand that to millions”
→ Read the source episode
Next generation Prima retinal prosthesis enters human clinical trials
Renee Haas predicts that within 5+ years, chip design from idea to GDS2 file will be possible for certain designs, likely using AI tooling.
Renee Haas predicts that semiconductor supply chain constraints will persist for 3-5 years at minimum.
Max Hodak predicts that Cyens' in-house gene therapy will enter human trials within approximately one year
Max Hodak predicts that Cyens will make first commercial sales of Prima in Europe within weeks of July 2026
Brian Armstrong predicts New Limit will launch its first phase one clinical trial for epigenetic reprogramming in the next year (2027).
Eric Alabest predicts chess.com will launch additional games beyond chess and poker
Summaries are ours; the quote is a verbatim transcript excerpt. Our resolution criteria are editorial and disputable. How this works.